Including all individuals is not enough: Lessons for intention-to-treat analysis

被引:230
作者
White, Ian R. [1 ]
Carpenter, James [2 ]
Horton, Nicholas J. [3 ]
机构
[1] MRC, Biostat Unit, Cambridge CB2 2BW, England
[2] London Sch Hyg & Trop Med, Dept Med Stat, London WC1, England
[3] Smith Coll, Dept Math & Stat, Northampton, MA 01063 USA
基金
英国医学研究理事会;
关键词
OBSERVATION CARRY-FORWARD; MULTIPLE-IMPUTATION; CLINICAL-TRIALS; SENSITIVITY-ANALYSIS; MISSING VALUES; BASE-LINE; SELF-HELP; REGRESSION; COVARIATE; LOCF;
D O I
10.1177/1740774512450098
中图分类号
R-3 [医学研究方法]; R3 [基础医学];
学科分类号
1001 ;
摘要
Background Intention-to-treat (ITT) analysis requires all randomised individuals to be included in the analysis in the groups to which they were randomised. However, there is confusion about how ITT analysis should be performed in the presence of missing outcome data. Purposes To explain, justify, and illustrate an ITT analysis strategy for randomised trials with incomplete outcome data. Methods We consider several methods of analysis and compare their underlying assumptions, plausibility, and numbers of individuals included. We illustrate the ITT analysis strategy using data from the UK700 trial in the management of severe mental illness. Results Depending on the assumptions made about the missing data, some methods of analysis that include all randomised individuals may be less valid than methods that do not include all randomised individuals. Furthermore, some methods of analysis that include all randomised individuals are essentially equivalent to methods that do not include all randomised individuals. Limitations This work assumes that the aim of analysis is to obtain an accurate estimate of the difference in outcome between randomised groups and not to obtain a conservative estimate with bias against the experimental intervention. Conclusions Clinical trials should employ an ITT analysis strategy, comprising a design that attempts to follow up all randomised individuals, a main analysis that is valid under a stated plausible assumption about the missing data, and sensitivity analyses that include all randomised individuals in order to explore the impact of departures from the assumption underlying the main analysis. Following this strategy recognises the extra uncertainty arising from missing outcomes and increases the incentive for researchers to minimise the extent of missing data. Clinical Trials 2012; 9: 396-407. http://ctj.sagepub.com
引用
收藏
页码:396 / 407
页数:12
相关论文
共 65 条
[1]   The revised CONSORT statement for reporting randomized trials: Explanation and elaboration [J].
Altman, DG ;
Schulz, KF ;
Moher, D ;
Egger, M ;
Davidoff, F ;
Elbourne, D ;
Gotzsche, PC ;
Lang, T .
ANNALS OF INTERNAL MEDICINE, 2001, 134 (08) :663-694
[2]  
Altman Douglas G, 2009, Open Med, V3, pe51
[3]  
[Anonymous], PACKAGE NORM R PACKA
[4]  
[Anonymous], PUBLICATION NATL I H
[5]  
[Anonymous], SAS STAT 9 1 US GUID
[6]  
[Anonymous], PGVEZ00038 TNO PREV
[7]  
[Anonymous], 2010, PREV TREATM MISS DAT
[8]  
[Anonymous], 2012, FLEXIBLE IMPUTATION, DOI DOI 10.1201/B11826
[9]  
[Anonymous], 2010, Guideline on missing data in confirmatory clinical trials
[10]  
[Anonymous], GUID IND ANT DRUGS U